Alamar Biosciences, Inc.

During the three months ended June 30, 2026 noneof our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K.

The information set forth below is included herein for purposes of providing disclosure under various items of Form 8-K.

Item 1.01 Entry into a Material Definitive Agreement.

On August 6, 2026 (the “Effective Date”), the Company entered into a Third Amendment to Loan and Security Agreement (the “Third Amendment to Loan Agreement”), by and between the Company, as borrower, and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, as the lender (the “Lender”). The Third Amendment to Loan Agreement amends that certain Loan and Security Agreement, dated as of July 11, 2024, as amended by that certain First Amendment to Loan and Security Agreement, dated as of March 13, 2025, and that certain Second Amendment to Loan and Security Agreement, dated as of September 19, 2025 (the “Existing Loan Agreement”, as further amended by the Third Amendment to Loan Agreement, the “Amended Loan Agreement”). The Third Amendment to Loan Agreement provides for a revolving loan facility (the “Credit Facility”) in an aggregate principal amount of up to $60.0 million with an uncommitted accordion allowing for upsize up to $100.0 million upon Lender’s approval (the “Revolving Loans”). Pursuant to the Third Amendment to Loan Agreement, the term loan facility established under the Existing Loan Agreement was terminated. Proceeds from the Credit Facility may be used for working capital and general corporate purposes.

The Company has no obligation to draw down any amount under the Credit Facility, and did not draw down any amount on the Effective Date.

The Revolving Loans may be borrowed through the period beginning on the Effective Date through July 1, 2029 (the “Maturity Date”), at which time the Credit Facility terminates, and all outstanding Revolving Loans under the Credit Facility, together with all accrued and unpaid interest, must be repaid.

Borrowings under the Credit Facility accrue interest at a floating per annum rate of the greater of (i) the Prime Rate (as defined below) minus 0.5% and (ii) 6.0%. Prime Rate is defined as the rate of interest per annum published in The Wall Street Journal or any successor publication thereto as the “prime rate.” If such rate of interest from The Wall Street Journal becomes unavailable, the “Prime Rate” shall mean the rate of interest per annum announced by the Lender as its prime rate in effect. In each case, in the event such prime rate is less than zero, such rate shall be deemed to be zero for purposes of the Amended Loan Agreement.

On the Effective Date, the Company paid the Lender a commitment fee of $75,000. Upon termination of the Credit Facility, the Company will pay to the lender a contingent fee of $450,000. In addition, the Company will pay a quarterly unused line fee of 0.25% of the average unused portion of the Credit Facility, which shall be waived if the average daily balance of the Credit Facility during the applicable quarter is greater than $10.0 million.

The Company’s obligations under the Amended Loan Agreement are secured by a first lien on substantially all assets of the Company other than the Company’s intellectual property, with a negative pledge on the Company’s intellectual property.

The Amended Loan Agreement contains customary affirmative and negative covenants and customary events of default that permit the Lender to accelerate the Company’s outstanding obligations under the Amended Loan Agreement, all as set forth in the Amended Loan Agreement.

The foregoing description of the Third Amendment to Loan Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Third Amendment to Loan Agreement, a copy of which will be filed as an exhibit to our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information provided in Item 1.01 above is incorporated by reference into this Item 2.03.